• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Here's How I'm Trading Moderna Right Now

I'm long MRNA and have been since the beginning of the pandemic.
By STEPHEN GUILFOYLE
Nov 16, 2020 | 10:07 AM EST
Stocks quotes in this article: PFE, BNTX, MRNA

We already knew that the preliminary data released last week for the Phase 3 trials for Covid vaccine candidate BNT162b1 by Pfizer (PFE) and BioNTech (BNTX) were impressive. Very impressive in terms of both safety and efficacy. We knew that Moderna (MRNA) would soon release interim data for their closest candidate, mRNA-1273, and hopes were high, as both Pfizer an Moderna had made use of messenger RNA technology, an experimental method for creating an immune response to a viral infection that could, if it worked, cut years off of the length of the current public health crisis.

The federal government poured money into the effort across a plethora of pharmaceutical firms and bio-techs in an effort known as "Operation Warp Speed" to get there from here. Pfizer had secured a $1.95 billion contract from that program with the U.S. government for the first 100 million doses with an option to purchase 500 million more. Moderna had accepted $955 million in funds to help with development, as well as a contract allowing the government to purchase the first 100 million doses with an option to purchase 400 million more that brings the program's investment in the Moderna vaccine up to $2.48 billion.

I had hit send. Market Recon was already in editing. The Moderna news broke. My oldest Covid-related position. Stunningly effective at 94.5%. As far as we can tell rather safe too. Even more impressive that an efficacy rate that had been thought improbable just a few weeks ago, are the logistical concerns. While Pfizer's candidate must be stored at -94 degrees Fahrenheit, making widespread use of the military necessary as deep freeze capabilities just are not that common in the real worlds of medicine or food distribution networking.

Well, Moderna's candidate is far more user friendly from a logistics perspective. mRNA remains stable in range spanning 36 degrees F to 46 degrees F for 30 days, which is standard for a home refrigerator. In fact, mRNA remains stable for 12 hours at room temperature which will be huge at points of distribution. For long-term storage, mRNA does need to be kept at -4 degrees F. This vaccine does not require onsite dilution or special handling.

Details

You are going to have to wear your mask and socially distance through the holidays. Moderna expects to apply for Emergency Use Authorization from the FDA within weeks. Unfortunately there is not a lot of this vaccine ready to go. The firm says that they could deliver 20 million doses to the United States prior to year's end. Keep in mind that this vaccine is provided in two doses, 28 days apart, so that's 10 million people. Best case, should these two candidates (PFE & MRNA) both receive EMU authorization in short order, then 30 million Americans could be immunized this year. Moderna expects to produce between 500 million and 1 billion doses globally in 2021. The firm also has distribution deals with nations in Europe and the Middle East.

As for the Phase 3 study, Moderna had enrolled 30K healthy adult patients in their trials, 15K of whom were given the vaccine and 15K a placebo. Ninety-five individuals contracted a confirmed infection of SARS-Cov-2, 90 from the placebo group, and five from the vaccine group. There were 11 cases of severe Covid-19, all of whom came from the placebo group. The vaccine was considered to be generally safe, and well tolerated. Side effects did include pain at the injection site, and upon the "booster" dose, headaches, muscle pain, and fatigue.

So, What Now?

As people, we have to respect this awful virus. It's still out there, and it's still terrible. My next door neighbor had it, and did not even feel sick. I had it and it is easily the worst illness that I have ever gone through. Nothing else even comes close. So wear your mask, and stay as far away from people outside of your household as possible.

As for the stock, everyone knows I am long Moderna (MRNA)  and have been since the beginning of the pandemic. I am at a full position, having been overweight but having taken some off back during the summer spike. This morning, as the bell was about to ring, I was up 238% in this name. Of course I have to take some off. That's how trading works. Does not mean that the shares can not go higher.

What had looked like a cup with handle that ran summer into fall, now looks more like a period of consolidation type basing pattern running from the May spike into the present. This makes the $95 spot the pivot, where I had previously thought $80 to be the pivot.

With this morning's opening above my target price of $96, I am forced by my own code of discipline to take 20% of my long off and bank it. My new target price for the balance of this long position is now $114.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle was Long PFE, MRNA equity.

TAGS: Drug Approvals | Investing | Markets | Stocks | Technical Analysis | Trading | Biotechnology | Pharmaceuticals | Coronavirus

More from Investing

Stock Market Continues to Defy Conventional Wisdom

James "Rev Shark" DePorre
Jan 22, 2021 5:04 PM EST

Concerns about the action being overheated remain, but rotational action keeps the momentum going.

AMC Is a High Risk, High Reward Play

Timothy Collins
Jan 22, 2021 2:15 PM EST

Short and sweet: This is based on the high running emotions of the markets. There's little to it beyond that.

GoodRx Needs a Shot in the Arm to Improve Its Outlook

Bruce Kamich
Jan 22, 2021 2:03 PM EST

IPOs in recent months have done extremely well -- not so GDRX.

2021 and 2022 Look Difficult for Intel, While 2023 -- Might -- Be Better

Eric Jhonsa
Jan 22, 2021 1:44 PM EST

Competition from AMD and ARM CPU developers looks set to take a toll over the next two years. But Intel could be in better shape in 2023 if its new CEO is ready to make some tough choices.

GameStop and the Dangerous Game of Gamma Squeezes

Timothy Collins
Jan 22, 2021 1:26 PM EST

What happened after Citron Research posted a video about GameStop is very troubling.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:01 AM EST JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    I'll discuss price targets in my Saturday column.
  • 07:54 AM EST GARY BERMAN

    Friday Morning Fibocall for 1/22/2021

    SPX (Long-Term View) The 1/21/21 NEW high @ 3861...
  • 11:16 AM EST CHRIS VERSACE

    Worst Stocks to Buy for the Biden Presidency

    Biden's take on the minimum wage, likely moves on ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login